The treatment of intraperitoneal XXXX with monoclonal antibody guided 131I radiotherapy.

@entity1 @entity43 @entity5 @entity843 @entity902
Seven @entity1 with @entity43 , remaining after conventional therapy with surgery and a @entity902 containing chemotherapy regimen, were treated with intraperitoneal monoclonal antibody guided radiotherapy. 100 mCi131I conjugated to 10 mg of monoclonal antibody were injected i.p. in 2,000 ml peritoneal dialysis fluid. @entity1 were evaluated 3 months later; 3 had clinical progressive disease while third look laparotomy demonstrated progressive disease in 3 of the remaining 4 @entity1 . The seventh @entity1 did not have a third look laparotomy and is currently inevaluable for response. Five @entity1 with recurrent @entity5 not controlled by diuretics or repeated paracentesis were similarly treated with 75-170 mCi131I conjugated to 10 mg monoclonal antibody. In three @entity1 the @entity843 was controlled for a mean of 4 months. One @entity1 died too early to assess the control of his @entity843 but @entity5 cells disappeared from the ascitic fluid after therapy. In the @entity1 whose @entity843 were not controlled, a subpopulation of antigen-negative @entity5 cells was demonstrated. This study was unable to demonstrate a therapeutic benefit for i.p. injected monoclonal antibody guided radiotherapy for solid intraperitoneal @entity5 but suggests that it may be capable of controlling the accumulation of antigen positive @entity5 .
